This article has been corrected from a previous version, which contained factual errors regarding Clinical Data's vilazodone and Stedivaze programs. GenomeWeb regrets this inaccuracy.

NEW YORK (GenomeWeb News) – Clinical Data today reported that its second-quarter revenues increased 27 percent year over year, due to a 51 percent rise in gross sales of its Familion genetic tests, which are sold through the firm’s PGx Health division.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.